This training seminar is for University of Cambridge academics, clinicians and early-career researchers and is also open to biotech-based industry professionals.

Professional drug hunter Dr Olaf Ritzeler from Sanofi will talk through the drug discovery pathway from target selection to preclinical candidate nomination and focus in on data requirements – covering computational modelling & ‘omics’, through pharmacokinetics & pharmacodynamics to drug safety, regulatory and commercial data needs.

Jointly hosted by the Cambridge Academy of Therapeutic Sciences (CATS) and the Milner Therapeutics Institute, this seminar will unveil how the right datasets are crucial for the creation of new medicines.

It will be followed by a networking reception unitl 6.00pm

Speaker Biography

Dr. Olaf Ritzeler scouts and evaluates external R&D opportunities in Europe at all development stages with a therapeutic focus on rare diseases. He is working in a global, transversal team to which he brings his strong expertise on drug discovery and development. The research teams led by him have delivered one phase IIb-, two phase I-, five preclinical- and six lead candidates. His contribution to Sanofi’s drug-pipeline was awarded by the “Meilenstein Preis” and “Drug Hunter Award” for outstanding efforts and key contribution to drug innovation and approval.

Registrations are closed

Drug Discovery Seminar: Which data is required when and why?